Last reviewed · How we verify
GSK5464714- Camlipixant
At a glance
| Generic name | GSK5464714- Camlipixant |
|---|---|
| Also known as | Camlipixant |
| Sponsor | Bellus Health Inc. - a GSK company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK5464714- Camlipixant CI brief — competitive landscape report
- GSK5464714- Camlipixant updates RSS · CI watch RSS
- Bellus Health Inc. - a GSK company portfolio CI